Callan JMB, Inc. CJMB 深 滬
等待開盤 04-02 09:30:00 美东时间
1.25
0.000
0.00%
華盛通- 最 高1.2785
- 今 開1.21
- 成交量 2.48万股
- 最 低 1.17
- 昨 收 1.25
- 總市值 577.88万
- 52周最高 5.88
- 市盈率 靜 --
- 換手率 0.54%
- 52周最低 1.0815
- 委 比 0.00%
- 總股本 462.30万
- 歷史最高 7.7599
- 量 比 0.20
- 振 幅 8.68%
- 歷史最低 1.0815
- 每 手 1
- 風險率 1.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Callan Jmb Q4 EPS $(0.56), Sales $1.161M
Callan Jmb (NASDAQ:CJMB) reported quarterly losses of $(0.56) per share. The company reported $1.161 million in sales this quarter.
04-01 05:28
12 Industrials Stocks Moving In Friday's Intraday Session
Gainers Globavend Holdings (NASDAQ:GVH) shares increased by 36.0% to $1.4 duri...
03-28 01:05
Callan JMB joins DifGen, Aveva, Attune Biotech, SGP in JKB-122 immune platform scale-up collaboration; provides independent manufacturing and supply chain oversight
Callan JMB joins DifGen, Aveva, Attune Biotech, SGP in JKB-122 immune platform scale-up collaboration; provides independent manufacturing and supply chain oversight Callan JMB will act as an independent infrastructure and oversight partner in a collaboration led by DifGen Pharmaceuticals and Aveva D
03-27 20:45
Callan JMB Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2b/3 Advancement
<p>Callan JMB Inc. announced its role as an independent oversight partner in a collaboration led by DifGen Pharmaceuticals, Aveva Drug Delivery Systems, and Biostax Corp (doing business as Attune Biotech) to support U.S.-based manufacturing and supply chain operations for the JKB-122 (Lodonal™) immune restoration platform. The collaboration focuses on ensuring compliance with federal standards, particularly for Phase 2b/3 clinical development and...
03-27 12:45
Callan JMB Agrees With Attune Biotech To Support Its IND Clinical Trials For Treatment Of Post-Acute Sequelae Of SARS-CoV-2 Infection
Callan JMB will Provide Independent Manufacturing Oversight and Governance as lodonal™ Undergoes Clinical Trials for Underserved Patient Population SPRING BRANCH, Texas, March 11, 2026 (GLOBE NEWSWIRE) --
03-11 20:49
Callan JMB Inc. partners with Attune Biotech to oversee lodonal IND manufacturing and quality control
Callan JMB Inc. partners with Attune Biotech to oversee lodonal IND manufacturing and quality control Callan JMB agreed with Attune Biotech to oversee manufacturing and quality control for Attune’s investigational new drug clinical trials of lodonal for Long COVID. Under the agreement, Callan JMB wi
03-11 20:45
Callan JMB Inc. to Oversee Manufacturing and Quality Control of Attune Biotech’s IND Clinical Trials for lodonal™ in the Treatment of Long COVID
Callan JMB will provide independent manufacturing oversight for Attune Biotech's clinical trials targeting Long COVID, leveraging their logistics and regulatory expertise. The partnership aims to address the unmet needs of millions of patients with Long COVID, a condition without FDA-approved therapies.
03-11 12:45
Callan JMB CEO Wayne Williams to Attend 50th International GMP Conference
Callan JMB CEO Wayne Williams to Attend 50th International GMP Conference Callan JMB Inc. said CEO Wayne Williams has been invited to attend the 50th International GMP Conference in Athens, Georgia, scheduled for March 2-5, 2026. More information: https://internationalgmp.com/. Disclaimer: This news
03-02 21:45
Callan JMB CEO, Wayne Williams Invited to Attend the 50th International GMP Conference on March 2-5, 2026
Callan JMB首席执行官Wayne Williams受邀参加将于2026年3月2日至5日在Georgia州Athens市举行的第50届国际GMP会议。该会议由University of Georgia药学院和美国食品药品监督管理局(FDA)联合主办，是一次全球性的行业盛会。 Williams表示，受邀参加此次具有里程碑意义的会议深感荣幸，并期待与其他行业领袖共同探讨药品行业未来的发展趋势，同时希望将会议中的新见解带回公司，进一步提升公司在医疗物流和应急管理领域的领先地位，确保药品的高效安全配送。
03-02 13:45
Why STMicroelectronics Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of STMicroelectronics NV (NYSE:STM) rose sharply in pre-market trading a...
02-09 18:56
